Crystal structures of Sirt3 complexes with 4′-bromo-resveratrol reveal binding sites and inhibition mechanism

Chemistry and Biology

Volumn 20, Issue 11, 2013, Pages 1375-1385

  Nguyen, Giang Thi Tuyet ^a   Gertz, Melanie ^a   Steegborn, Clemens ^a  

^a UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4' BROMO RESVERATROL [5 [2 (4 HYDROXYPHENYL)VINYL]1,3 BENZENEDIOL]; HYDROXYL GROUP; PICEATANNOL; POLYPHENOL; SIRTUIN 1; SIRTUIN 3; UNCLASSIFIED DRUG; 5-(2-(4-BROMOPHENYL)VINYL)-1,3-BENZENEDIOL; RESORCINOL DERIVATIVE; SIRT1 PROTEIN, HUMAN; SIRT3 PROTEIN, HUMAN; STILBENE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLIZATION; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN CONFORMATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RESORCINOLS; SIRTUIN 1; SIRTUIN 3; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84888306269     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2013.09.019     Document Type: Article

References (57)

1. J.L. Avalos, K.M. Bever, and C. Wolberger Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme Mol. Cell 17 2005 855 868
2. M.T. Borra, M.R. Langer, J.T. Slama, and J.M. Denu Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases Biochemistry 43 2004 9877 9887
3. M.T. Borra, B.C. Smith, and J.M. Denu Mechanism of human SIRT1 activation by resveratrol J. Biol. Chem. 280 2005 17187 17195
4. L. Chen Medicinal chemistry of sirtuin inhibitors Curr. Med. Chem. 18 2011 1936 1946
5. V.B. Chen, W.B. Arendall 3rd, J.J. Headd, D.A. Keedy, R.M. Immormino, G.J. Kapral, L.W. Murray, J.S. Richardson, and D.C. Richardson MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr. D Biol. Crystallogr. 66 2010 12 21
6. H.Y. Cohen, C. Miller, K.J. Bitterman, N.R. Wall, B. Hekking, B. Kessler, K.T. Howitz, M. Gorospe, R. de Cabo, and D.A. Sinclair Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase Science 305 2004 390 392
7. J.S. Disch, G. Evindar, C.H. Chiu, C.A. Blum, H. Dai, L. Jin, E. Schuman, K.E. Lind, S.L. Belyanskaya, and J. Deng Discovery of thieno[3,2-d]pyrimidine- 6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3 J. Med. Chem. 56 2013 3666 3679
8. J. Du, Y. Zhou, X. Su, J.J. Yu, S. Khan, H. Jiang, J. Kim, J. Woo, J.H. Kim, and B.H. Choi Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase Science 334 2011 806 809
9. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132
10. F. Fischer, M. Gertz, B. Suenkel, M. Lakshminarasimhan, M. Schutkowski, and C. Steegborn Sirt5 deacylation activities show differential sensitivities to nicotinamide inhibition PLoS ONE 7 2012 e45098
11. R.A. Frye Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins Biochem. Biophys. Res. Commun. 273 2000 793 798
12. M. Gertz, and C. Steegborn Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia Biochim. Biophys. Acta 1804 2010 1658 1665
13. M. Gertz, G.T. Nguyen, F. Fischer, B. Suenkel, C. Schlicker, B. Fränzel, J. Tomaschewski, F. Aladini, C. Becker, D. Wolters, and C. Steegborn A molecular mechanism for direct sirtuin activation by resveratrol PLoS ONE 7 2012 e49761
14. M. Gertz, F. Fischer, G.T.T. Nguyen, M. Lakshminarasimhan, M. Schutkowski, M. Weyand, and C. Steegborn Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism Proc. Natl. Acad. Sci. USA 110 2013 E2772 E2781
15. C. Gille, and C. Frömmel STRAP: editor for STRuctural Alignments of Proteins Bioinformatics 17 2001 377 378
16. L. Guarente Calorie restriction and SIR2 genes - towards a mechanism Mech. Ageing Dev. 126 2005 923 928
17. L. Guarente, and F. Picard Calorie restriction - the SIR2 connection Cell 120 2005 473 482
18. M.C. Haigis, and D.A. Sinclair Mammalian sirtuins: biological insights and disease relevance Annu. Rev. Pathol. 5 2010 253 295
19. M.C. Haigis, R. Mostoslavsky, K.M. Haigis, K. Fahie, D.C. Christodoulou, A.J. Murphy, D.M. Valenzuela, G.D. Yancopoulos, M. Karow, and G. Blander SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells Cell 126 2006 941 954
20. A.S. Hebert, K.E. Dittenhafer-Reed, W. Yu, D.J. Bailey, E.S. Selen, M.D. Boersma, J.J. Carson, M. Tonelli, A.J. Balloon, and A.J. Higbee Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome Mol. Cell 49 2013 186 199
21. K.G. Hoff, J.L. Avalos, K. Sens, and C. Wolberger Insights into the sirtuin mechanism from ternary complexes containing NAD+ and acetylated peptide Structure 14 2006 1231 1240
22. K.T. Howitz, K.J. Bitterman, H.Y. Cohen, D.W. Lamming, S. Lavu, J.G. Wood, R.E. Zipkin, P. Chung, A. Kisielewski, and L.L. Zhang Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 2003 191 196
23. H.C. Hsu, C.L. Wang, M. Wang, N. Yang, Z. Chen, R. Sternglanz, and R.M. Xu Structural basis for allosteric stimulation of Sir2 activity by Sir4 binding Genes Dev. 27 2013 64 73
24. B.P. Hubbard, A.P. Gomes, H. Dai, J. Li, A.W. Case, T. Considine, T.V. Riera, J.E. Lee, S.Y. e, and D.W. Lamming Evidence for a common mechanism of SIRT1 regulation by allosteric activators Science 339 2013 1216 1219
25. L. Jin, W. Wei, Y. Jiang, H. Peng, J. Cai, C. Mao, H. Dai, W. Choy, J.E. Bemis, and M.R. Jirousek Crystal structures of human SIRT3 displaying substrate-induced conformational changes J. Biol. Chem. 284 2009 24394 24405
26. W. Kabsch Xds Acta Crystallogr. D Biol. Crystallogr. 66 2010 125 132
27. M. Kaeberlein, T. McDonagh, B. Heltweg, J. Hixon, E.A. Westman, S.D. Caldwell, A. Napper, R. Curtis, P.S. DiStefano, and S. Fields Substrate-specific activation of sirtuins by resveratrol J. Biol. Chem. 280 2005 17038 17045
28. M. Lakshminarasimhan, D. Rauth, M. Schutkowski, and C. Steegborn Sirt1 activation by resveratrol is substrate sequence-selective Aging (Albany, N.Y. Online) 5 2013 151 154
29. M. Lakshminarasimhan, U. Curth, S. Moniot, S. Mosalaganti, S. Raunser, and C. Steegborn Molecular architecture of the human protein deacetylase Sirt1 and its regulation by AROS and resveratrol Biosci. Rep. 33 2013 e00037
30. G. Laurent, N.J. German, A.K. Saha, V.C. de Boer, M. Davies, T.R. Koves, N. Dephoure, F. Fischer, G. Boanca, and B. Vaitheesvaran SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase Mol. Cell 50 2013 686 698
31. S. Michan, and D. Sinclair Sirtuins in mammals: insights into their biological function Biochem. J. 404 2007 1 13
32. J.C. Milne, P.D. Lambert, S. Schenk, D.P. Carney, J.J. Smith, D.J. Gagne, L. Jin, O. Boss, R.B. Perni, and C.B. Vu Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes Nature 450 2007 712 716
33. S. Moniot, M. Weyand, and C. Steegborn Structures, substrates, and regulators of Mammalian sirtuins - opportunities and challenges for drug development Front Pharmacol 3 2012 16
34. S. Moniot, M. Schutkowski, and C. Steegborn Crystal structure analysis of human Sirt2 and its ADP-ribose complex J. Struct. Biol. 182 2013 136 143
35. U. Mueller, N. Darowski, M.R. Fuchs, R. Förster, M. Hellmig, K.S. Paithankar, S. Pühringer, M. Steffien, G. Zocher, and M.S. Weiss Facilities for macromolecular crystallography at the Helmholtz-Zentrum Berlin J. Synchrotron Radiat. 19 2012 442 449
36. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
37. T. Nakagawa, D.J. Lomb, M.C. Haigis, and L. Guarente SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle Cell 137 2009 560 570
38. A.D. Napper, J. Hixon, T. McDonagh, K. Keavey, J.F. Pons, J. Barker, W.T. Yau, P. Amouzegh, A. Flegg, and E. Hamelin Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 J. Med. Chem. 48 2005 8045 8054
39. J.C. Newman, W. He, and E. Verdin Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease J. Biol. Chem. 287 2012 42436 42443
40. G.T. Nguyen, S. Schaefer, M. Gertz, M. Weyand, and C. Steegborn Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism Acta Crystallogr. D Biol. Crystallogr. 69 2013 1423 1432
41. B.J. North, B.L. Marshall, M.T. Borra, J.M. Denu, and E. Verdin The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase Mol. Cell 11 2003 437 444
42. M. Pacholec, J.E. Bleasdale, B. Chrunyk, D. Cunningham, D. Flynn, R.S. Garofalo, D. Griffith, M. Griffor, P. Loulakis, and B. Pabst SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 J. Biol. Chem. 285 2010 8340 8351
43. S.-J. Park, F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, H. Rehmann, R. Taussig, and A.L. Brown Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases Cell 148 2012 421 433
44. L. Pirola, and S. Fröjdö Resveratrol: one molecule, many targets IUBMB Life 60 2008 323 332
45. S. Rahman, and R. Islam Mammalian Sirt1: insights on its biological functions Cell Commun. Signal. 9 2011 11
46. A. Šali, and T.L. Blundell Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 234 1993 779 815
47. B.D. Sanders, B. Jackson, and R. Marmorstein Structural basis for sirtuin function: what we know and what we don't Biochim. Biophys. Acta 1804 2010 1604 1616
48. A.A. Sauve, and D.Y. Youn Sirtuins: NAD(+)-dependent deacetylase mechanism and regulation Curr. Opin. Chem. Biol. 16 2012 535 543
49. A.A. Sauve, C. Wolberger, V.L. Schramm, and J.D. Boeke The biochemistry of sirtuins Annu. Rev. Biochem. 75 2006 435 465
50. A.W. Schüttelkopf, and D.M. van Aalten PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. D Biol. Crystallogr. 60 2004 1355 1363
51. J.M. Solomon, R. Pasupuleti, L. Xu, T. McDonagh, R. Curtis, P.S. DiStefano, and L.J. Huber Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage Mol. Cell. Biol. 26 2006 28 38
52. B.G. Szczepankiewicz, H. Dai, K.J. Koppetsch, D. Qian, F. Jiang, C. Mao, and R.B. Perni Synthesis of carba-NAD and the structures of its ternary complexes with SIRT3 and SIRT5 J. Org. Chem. 77 2012 7319 7329
53. A.A. Vagin, and M.N. Isupov Spherically averaged phased translation function and its application to the search for molecules and fragments in electron-density maps Acta Crystallogr. D Biol. Crystallogr. 57 2001 1451 1456
54. E. Verdin, M.D. Hirschey, L.W.S. Finley, and M.C. Haigis Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling Trends Biochem. Sci. 35 2010 669 675
55. J.M. Villalba, and F.J. Alcaín Sirtuin activators and inhibitors Biofactors 38 2012 349 359
56. C.J. Wienken, P. Baaske, U. Rothbauer, D. Braun, and S. Duhr Protein-binding assays in biological liquids using microscale thermophoresis Nat Commun 1 2010 100
57. X. Zhao, D. Allison, B. Condon, F. Zhang, T. Gheyi, A. Zhang, S. Ashok, M. Russell, I. Macewan, and Y. Qian The 2.5 A crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analog) reveals a novel mechanism of histone deacetylase inhibition J. Med. Chem. 56 2013 761 780